A series of 1-thia-4-azaspiro[4.5]decan-3-ones bearing an amide group at C-4 and various substitutions at C-2 and C-8 were synthesized and evaluated against human coronavirus and influenza virus. Compounds 7m, 7n, 8k, 8l, 8m, 8n, and 8p were found to inhibit human coronavirus 229E replication. The most active compound was 
| INTRODUCTION
Coronaviruses (CoVs) are a large family of enveloped RNA viruses with positive-sense single-stranded RNA genome, affecting a wide range of animal species. Some widely spread human coronaviruses (HCoVs, i.e., strains 229E, OC43, NL63, and HKU1) are the etiologic agents in 15-30% of common cold disease, [1] a relatively benign yet highly contagious respiratory illness that can possibly be complicated by virus-induced asthma or exacerbations of chronic obstructive pulmonary disease. [2] These HCoVs can also cause high-morbidity lower respiratory tract conditions, such as pneumonia, bronchiolitis, and croup, especially in immunocompromised patients, the elderly and young children. [3] [4] [5] Besides, two highly pathogenic CoVs originating from animal reservoirs have had a major medical and socio-economic impact. In 2003, the newly discovered SARS-CoV [6] responsible for the severe acute respiratory syndrome, suddenly emerged in South-East Asia, after which it caused 8096 infections worldwide with a case-fatality (CFR) rate of 9.6% and a total societal cost estimated at 40 billion USD. [7] In 2012, the thus far unknown Middle East Respiratory Syndrome virus (MERS-CoV) appeared [6] which, to date, caused 2249 cases with a CFR of 36%. [8] The high virulence of SARS-and MERS-CoVs, combined with their sudden emergence and clear pandemic potential, has boosted the development of preventive (i.e., vaccines) or therapeutic (i.e., antiviral drugs)
interventions to address serious CoV infections in humans. Thus far, except for quarantine measures, no effective intervention exists.
In our laboratory, we initiated a small-molecule screening program in HCoV-infected cells, aimed at identifying new chemical entities and CoV targets with relevance for antiviral drug development. In the present report, we describe the identification of a new class of CoV inhibitors carrying a 1-thia-4-azaspiro [4.5] decan-3-one scaffold (Scheme 1). A series of structural analogs were chemically synthesized to delineate the structure-activity relationship. Intriguingly, the same scaffold is present in a class of H3 hemagglutininspecific influenza virus fusion inhibitors that was discovered by our team some time ago. [9] This points to the 1-thia-4-azaspiro[4.5]-decan-3-one scaffold as a versatile chemical structure with high relevance for antiviral drug development.
| RESULTS AND DISCUSSION

| Chemistry
Hydrazides (3, 4) were obtained by stepwise reactions, firstly by esterification of acids in methanol in the presence of H 2 SO 4 to give esters (1, 2) , and secondly hydrazinolysis of 1, 2 to give 3, 4.
[10] 3, 4 were reacted with cyclic ketones to afford corresponding derivatives 5, 6 that are commercially available or recorded earlier, except 5a and 6a. [11, 12] Spectral and analytical data of 5a and 6a are given under "General . Bands between 3468-3167 cm −1 region confirmed the presence of NH stretching bands. In the 1 H-NMR spectra of 7, CONH protons were observed at δ 9.91-10.59 ppm as singlets. C 2 -methylene protons of 7a-g and 8a-h resonated at δ 3.52-3.64 ppm as singlets, while C 2 -methine protons of 7h-n and 8i-p gave quartets at δ 3. Seven compounds, i.e. 7m, 7n, 8k, 8l, 8m, 8n, and 8p, were found to inhibit human coronavirus 229E with low cytotoxicity (Table 1 ). The compounds showing activity all carry a methyl substituent at the C-2 position of the azaspiro [4.5] decane (R 1 ), whereas the unmethylated analogs (i.e., 7e, 7f, 8c, 8d, 8e, 8f, 8h) were devoid of antiviral activity. The same observation was previously made for the structurally related influenza virus fusion inhibitors. [9] In addition, for compound series 8, the anti-coronavirus activity clearly depended on the bulkiness of the C-8 substituent of the azaspiro [4.5] 7a 
| Synthesis of methyl phenoxyacetate (1) or methyl 3-phenylpropanoate (2)
A solution of phenoxyacetic acid (0.01 mol) or 3-phenylpropionic acid (0.01 mol) and sulfuric acid (98%) (0.1 ml) in 50 ml of methanol was heated for 24 hr. The solution was neutralized with 0.01 mol of sodium bicarbonate solution, the mixture was extracted with diethyl ether and, after distillation of solvent, the ester was used without further purification. [10, 13] 
| Synthesis of 2-phenoxyacetohydrazide (3) or 3-phenylpropane-hydrazide (4)
A mixture of 1 or 2 (0.01 mol), ethanol (50 ml), and hydrazine (0.0125 mol) was refluxed for 1 hr. The solid was filtered off, washed with cold water and used without recrystallization. [10, 13] 4.1.4 | General procedure for the synthesis of
A solution of hydrazide (3 or 4) and appropriate ketone (0.01 mol) in 20 ml of ethanol (96%) was refluxed for 1-3 hr and then the solution was allowed to cool. The solid thus formed was filtered off, dried and directly used in the next step. | 5 of 9 CH 3 ), 1.24-1.45 (2H, m, spirodecane C 7,9-ax -H), 1.50 (1H, broad d, J = 13 Hz, spirodecane C 8-eq -H), 1.56-1.78 (6H, m, C 6,10 -H, C 7,9-eq -H), (6H, m, spirodecane C 7,9-eq -H, C 6,10 -H), 3.85 (H, q, J = 7 Hz, spirodecane 
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